Literature DB >> 6292827

Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes.

H Castro-Malaspina, M A Moore.   

Abstract

In this article current concepts on the regulation of bone marrow collagen are reviewed and a hypothesis regarding the mechanisms leading to marrow fibrosis associated with Primary Myelofibrosis (PMF) is presented. Type I and type III collagen, products of marrow fibroblasts, are the main constituents of myelofibrotic tissue and megakaryocytes are the predominant cells proliferating in PMF. There is evidence for the clonal nature of the hematopoietic cell proliferation and the secondary origin of myelofibrosis. Also, evidence exists indicating that defective megakaryocyte maturation, i.e. ineffective megakaryocytopoiesis occurs in patients with PMF. It is postulated that ineffective megakaryocytopoiesis leads to an excessive concentration of megakaryocyte components in the marrow intercellular space and that the development of marrow fibrosis involves mainly 2 megakaryocytic products: growth factor and factor 4. The growth factor stimulates fibroblast proliferation and collagen secretion. Factor 4 inhibits the activity of the enzyme collagenase. Thus, the imbalance between increased collagen production and decreased collagen degradation leads to an excessive deposition of collagens in bone marrow matrix.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292827

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  12 in total

1.  Acute myelofibrosis in megakaryoblastic leukemia with translocation between chromosomes 8 and 14.

Authors:  M Winkelmann; C Aul; R E Scharf; A Schmitt-Gräff; F Carbonell; J L Villeval; H Grosse-Wilde; J T Fischer; W Schneider
Journal:  Klin Wochenschr       Date:  1987-11-02

2.  Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings.

Authors:  R Burkhardt; R Bartl; K Jäger; B Frisch; G Kettner; G Mahl; M Sund
Journal:  J Clin Pathol       Date:  1986-03       Impact factor: 3.411

3.  Acquired refractory anaemia with excess of blasts of promegakaryoblastic type.

Authors:  S Woessner; R Lafuente; L Florensa; R M Vilá; J Sans-Sabrafen
Journal:  Blut       Date:  1986-10

4.  Perisinusoidal fibrosis of the liver in patients with thrombocytopenic purpura.

Authors:  M E Lafon; P Bioulac-Sage; J A Grimaud; L Boussarie; J P Merlio; J Reiffers; C Balabaud
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

5.  Myelosuppression in polycythemia vera: chemotherapy or radiotherapy?

Authors:  Y Najean; C Dresch
Journal:  Blut       Date:  1982-01

6.  Megakaryoblastic micromegakaryocytic crisis in chronic myeloid leukemia.

Authors:  G Lingg; F Schmalzl; J Breton-Gorius; A Tabilio; H E Schaefer; D Geissler; M Schweiger; W Kirchmair
Journal:  Blut       Date:  1985-10

7.  Gray platelet syndrome: selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover.

Authors:  M Köhler; P Hellstern; E Morgenstern; C Mueller-Eckhardt; R Berberich; R J Meiser; P Scheffler; E Wenzel
Journal:  Blut       Date:  1985-06

8.  Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.

Authors:  A Tichelli; A Gratwohl; C Berger; A Lori; A Würsch; A Dieterle; C Thomssen; C Nissen; E Holdener; B Speck
Journal:  Blut       Date:  1989-01

9.  Idiopathic acquired sideroblastic anaemia transforming to acute myelosclerosis.

Authors:  A C Bested; G Cheng; P H Pinkerton; O Kassim; J S Senn
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

10.  Myelofibrosis: Review of clinical and pathological features in fourteen dogs.

Authors:  B Hoff; J H Lumsden; V E Valli; S A Kruth
Journal:  Can Vet J       Date:  1991-06       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.